Blood – components, testing & collection market
Upcoming SlideShare
Loading in...5
×
 

Blood – components, testing & collection market

on

  • 577 views

Market report gives an insight into global Blood - Components, Testing & Collection market. The report also provides market analytics by Product Type. The market is divided by Type into Blood ...

Market report gives an insight into global Blood - Components, Testing & Collection market. The report also provides market analytics by Product Type. The market is divided by Type into Blood Components and Blood Testing & Collecting Devices and Other (Artificial Blood and Research) ; and by Blood Products into Plasma Products, Cellular Components, and Whole Blood; and Blood Testing & Collecting Devices into Management and Monitoring Instruments, Immunoassays and Other. Information regarding latest products & technologies also find a mention in the report. Projections and estimates are also illustrated by geographic regions encompassing North America, Europe, Japan, Asia-Pacific, and Rest of World (RoW) with 148 exclusive graphically represented exhibits. Compilation of Worldwide Patents and Research related to Blood and related products are also provided.

Statistics

Views

Total Views
577
Views on SlideShare
577
Embed Views
0

Actions

Likes
0
Downloads
8
Comments
0

0 Embeds 0

No embeds

Accessibility

Categories

Upload Details

Uploaded via as Adobe PDF

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment

Blood – components, testing & collection market Blood – components, testing & collection market Document Transcript

  • BLOOD-COMPONENTS, TESTING & COLLECTION MARKET SIZE Scope of the Study This report gives an insight on different areas of Blood – Components, Testing & Collection. Blood Research and Products include Blood Products, Blood Banking Devices (Such as Equipment involved in Collecting, Processing and Storing Blood and Blood Components), Blood Testing and Other (Such as Artificial Blood, Cord Blood and Recombinant Factors). Blood Products include Cellular Blood Components, Whole Blood and Plasma Derived Products (Immunoglobulins, Coagulation factors, Alpha-1 proteinase inhibitors, Albumins, Fibrin and Anti-Coagulants). Blood Testing includes Immunoassays, NAT and Other. The report provides an in depth analysis of each of the type and product areas by their respective categories. The study includes estimates and projections for the total global Blood Research and Products market and also key regional markets that include North America, Europe, Japan, Asia-Pacific and Rest of World. Estimates and projections are illustrated graphically. Business profiles of 42 major companies are discussed in the report. The report serves as a guide to global Blood industry, as it covers more than 213 companies that are engaged in Blood Products R&D, discovery, testing and supply of products and services. Major Contract Research Organizations serving Blood Products industry are also covered in the Corporate Directory section of this report. Information related to recent product releases, product developments, partnerships, collaborations, and mergers and acquisitions is also covered in the report. Blood Research and Products report is an ideal research tool providing strategic business intelligence to the corporate sector. This report may help strategists, investors, laboratories, pharmaceutical companies, contract research organizations, biotechnology companies and drug approval authorities in --  Gauging Competitive Intelligence  Identifying Key Growth Areas and Opportunities  Understanding Geographic Relevance to Product  Knowing Regional Market Sizes and Growth Opportunities and Restraints  Keeping Tab on Emerging Technologies  Equity Analysis  Tapping New Markets
  • Analytics and Data Presented in this Report Pertain to Several Parameters Such as –  Global And Regional Market Sizes, Market Shares, Market Trends  Product (Global And Regional) Market Sizes, Market Shares, Market Trends  Technology Trends  Corporate Intelligence  Key Companies By Sales, Brands, Products  Consumer Behavioral Patterns  Other Strategic Business Affecting Data Research Methodology RI Technologies publishes business intelligence reports by going through a cycle of diligent research and analysis activity. Research is done using both online and offline resources. The study outline of this report is sketched on the following lines – global market analysis, regional market analysis, product segmentation, global and regional market analysis by product segment, market trends, M&A, R&D, competitive landscape, technology trends, and other key drivers. Current data helps in analyzing the future of the industry and is also helpful for doing market evaluations, and estimating the market size for the future. This report is uniquely researched and the methodology includes:  Need and Scope of Study  Product Definitions  Segmental Analysis  Regional Analysis  Exclusive Data Analytics  Corporate Intelligence  Feedback Right from concept to final compilation of this report, both primary and secondary research methods are applied. We have provided exclusive feedback forms/pre-release questionnaires for this report to use the information for authentication of our own findings. Secondary research includes government publications, investment research reports, web based surveys, website information of both companies and markets, and other offline resources such as print publications and CDs. Our compilation of easy to navigate PDF reports is essential value addition resources for leading and growing companies.
  • II. REPORT SYNOPSIS Introduction to Blood Blood is a fluid tissue made of a fluid matrix called plasma in which blood corpuscles are suspended. Blood corpuscles include red blood cells [RBCs] or erythrocytes, white blood cells [WBCs] or leukocytes and platelets. Mature erythrocytes in circulation are non-nucleated and play a role in the transport of oxygen to tissues. Leukocytes are broadly divided into granulocytes and agranulocytes. Granulocytes are basophils, eosinophils and neutrophils, while agranulocytes are lymphocytes and monocytes.. Blood also contains a small number of stem cells which can differentiate into other types of blood cells. Leukocytes play different roles and are important in immune response. Blood platelets are involved in hemostasis or blood coagulation. Functions of Blood Functions of blood can be grouped under three headings of transport, regulation and protection. Transport Functions These functions include the following:  A continuous exchange of components of blood with tissue fluids develops a balance between electrolyte and fluid.  Blood carries hormones from the endocrine system to the target organs or cells inside the body.  Blood carries waste products from cells to the exterior principally through the kidneys.  Blood carries CO2 from different areas of the body to the lungs.  Blood carries O2 and other nutrients to different areas of the body  Blood enables the elimination of waste like lactic acid, urea and CO2.  Blood delivers nutrients to different areas of the body from the digestive system Regulation Functions These functions include the following:  Blood participates in pH regulation via the action of buffers.  Blood plays an essential role in electrolyte and fluid balance. This takes place as the plasma proteins and salts promote osmotic pressure  Blood helps in regulation of body temperature. This is accomplished by eliminating heat from active areas like the skeletal muscles and carrying the same to the skin or other areas from where dissipation of the heat occurs.
  • Protection Functions These functions include the following  Blood maintains the temperature of the body by the circulation of heat.  Blood protects the body from getting infected or injured through the inflammatory mechanism.  Blood protects the body against aggression from foreign living organisms through the generation of antibodies and white blood cells.  Blood protects the body against disease via antibodies in blood plasma that react with the agents of aggression.  Blood aids in defending the body against microorganisms by the generation of phagocytic white-blood cells that devour and destroy them.  When blood vessels get damaged the blood clotting mechanism presents itself to prevent loss of fluid via hemorrhage. Hematology A branch of biology or physiology, pathology, clinical laboratory, internal medicine and pediatrics that is related to the study of blood, the blood producing organs and blood disorders is called hematology or haematology. Hematology involves the study of etiology, diagnosis, treatment, prognosis and prevention of blood disorders. Blood disorders disrupt the mechanism of formation of blood and its constituents like blood cells, hemoglobin, blood proteins and the system of coagulation. Standard Clinical Hematology Tests The complete blood count or the CBC is also called full blood count or the FBC. It is a test which involves white blood cell count, platelet count, hemoglobin level and several factors involving red blood cells. Coagulation is a specialty under hematology. Standard coagulation tests include the prothrombin time or the PT and partial thromboplastin time or the PTT. Another popular hematology test is the erythrocyte sedimentation rate or the ESR. The Coombs test is a standard test conducted in a blood bank. Categories of Hematological Disorders Some of the significant hematologic disorders may be segregated as follows:  Hemoglobinopathies – a congenital abnormality of the hemoglobin molecule or of the rate of hemoglobin synthesis.  Anemia which is the lack of red blood cells or hemoglobin.  Hematological malignancies.  Coagulopathies which are disorders of bleeding and coagulation.
  • Analyzing Hematological Disorders Some of the various methods employed to analyze hematological issues are:  Full blood count  Erythrocyte sedimentation rate or the ESR  Blood film  Bone marrow examination  Coombs test  Diascopy  Serum Ferritin level  Vitamin B12 and Folate levels  Prothrombin time  Partial thromboplastin time  Protein electrophoresis  Hemoglobin electrophoresis  D-dimer  EOS Therapies for Hematological Disorders Some of the therapies for hematologic disorders are:  Suggestions on diet  Prescription pharmaceuticals  Anticoagulation therapy.  Intramuscular injections, Vitamin B12 injections  Blood transfusion (anemia)  Venesection (iron overload or polycythemia)  Bone marrow transplant (leukemia)  Chemotherapy (leukemia)  Radiotherapy (leukemia)
  • Segmentation of Blood – Components, Testing & Collection Market Exhibit 1. Segmentation of Global Blood – Components, Testing & Collection Market by Product Type Product Type Blood Components Blood Testing & Collecting Devices *Other *Other Includes Artificial Blood and Research © RIT, 2013 Exhibit 2. Segmentation by Blood Components & Blood Testing and Collecting Devices Blood Components Blood Testing and Collecting Devices Plasma Products Management and Monitoring Instruments Cellular Components Immunoassays Whole Blood ^Other ^Other Includes Nucleic Acid Test (NAT) and Blood Grouping © RIT, 2013 The term “Blood – Components, Testing & Collection refers to Blood Components, Blood Collection Devices and Blood Testing Equipment employed during blood transfusion, collection / storage and microbial detection.
  • III. MARKET DYNAMICS Market Overview Europe and the US together account for almost 2/3rd of global Blood – Components, Testing & Collection market. The blood components market is estimated to constitute about XX% of the global market in 2015. Automated blood collection and processing systems as well as prior-screening capabilities of latest assays are expected to enhance quantity and quality of blood. Global Market Analysis The global Blood – Components, Testing & Collection market is predicted to touch US$XX billion by 2020 at a CAGR of 11.54%, from an estimated US$XX billion in 2012. North America is the largest market with a share of XX% closely followed by Europe and Japan with XX% and XX% respectively. Asia-Pacific market is projected to represent the fastest growing market with a CAGR of XX% throughout the analysis period. Japan represents the second fastest growing market closely followed by Europe and North America at a CAGR of XX% and XX% respectively.
  • Exhibit 3. Blood - Components, Testing & Collection – Global Value Market Estimations & Predictions (2005 -2020) by Geographic Region for North America, Europe, Japan, Asia-Pacific and Rest of World in US$ Billion Year/Region North America Europe Japan Asia-Pacific Rest of World Total 2005 XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX 2006 XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX 2007 XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX 2008 XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX 2009 XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX 2010 XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX 2011 XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX 2012 XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX 2013 XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX 2014 XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX 2015 XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX 2016 XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX 2017 XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX 2018 XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX 2019 XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX 2020 XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX CAGR% XX.XX XX.XX XX.XX XX.XX XX.XX 11.54 © RIT Figures, 2013 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 US$ Billion North America Europe Asia-Pacific Latin America Rest of World
  • Exhibit 4. Blood - Components, Testing & Collection – Global Value Market Shares (2010, 2015 & 2020) by Geographic Region for North America, Europe, Japan, Asia-Pacific and Rest of World Year/Region North America Europe Japan Asia-Pacific Rest of World Total 2010 XX.XX XX.XX XX.XX XX.XX XX.XX 100 2015 XX.XX XX.XX XX.XX XX.XX XX.XX 100 2020 XX.XX XX.XX XX.XX XX.XX XX.XX 100 © RIT Figures, 2013 Tainted Blood Products and Affected Hemophiliacs Hemophilia or bleeders disease is a hereditary disorder and the mutant gene responsible for it is X- chromosome linked. The disorder arises as a result of deficiency of clotting factors that are necessary for blood coagulation. In type hemophilia-A clotting factor VIII is wanting while in hemophilia-B clotting factor IX is deficient. Hemophilia-A is more common than the other. Since it is an inherited disease there is no permanent cure. But injection of the deficient clotting factor will be the remedy. Some people need it almost every alternate day. Tainted Blood Products and Health Hazard There have been several instances that exposed the callous attitudes of certain pharmaceutical companies that manufactured blood products contaminated with HIV [human immunodeficiency virus] and HCV [hepatitis C virus] and marketing them despite knowing the truth. Health havoc was caused to several hemophiliacs who were administered these blood products. Clotting factors were manufactured and introduced into the market by US based Armour Pharmaceutical Company, Cutter Biological division of Bayer Corporation, Hyland Pharmaceutical division of Baxter
  • International and Alpha Therapeutic Corporation. In earlier days [late 1970s to early 1980s] there was no proper procedure available to detect the presence of HIV in blood samples. Earlier it was thought AIDS spreads only by homosexual behavior and IV drug injections. But in mid 1980s USCDCP [United States Centers for Disease Control and Prevention] reported the occurrence of this disease in three hemophiliacs. This raised the suspicion that AIDS is perhaps transmitted via blood products. But lack of sensitive detection test for HIV in the blood samples of donors stood in the way to establish transmission of this disease from plasma donors. By the beginning of the year 1983, evidences pointed out the plasma products as the source of HIV transmission. Subsequently, USCDCP strongly criticized the manufacturers of blood products as responsible for the prevalence of AIDS in hemophilia patients. The use of tainted blood products manufactured in US not only affected hemophiliacs in US, but also in other countries that imported them. Though the number of people who developed the diseases varied from one country to another, the contributory factors for the development and spread of the blood borne diseases were almost similar. Exhibit 5. List of Global Major Companies Company Name Region Website Affinity Biologicals Canada www.affinitybiologicals.com Astrazeneca, Plc UK www.astrazeneca.com BioTime, Inc. USA www.biotimeinc.com Caridian BCT, Inc. USA www.caridianbct.com Cord Blood Registry USA www.cordbloodbank.com CSL Behring USA www.cslbehring.com Daxor Corporation USA www.daxor.com Fresenius SE Germany www.fresenius.se Fujirebio Diagnostics, Inc., USA www.fdi.com Gambro AB Sweden www.gambro.com Gen-Probe, Inc. USA www.gen-probe.com More…. © RIT Figures, 2013
  • Type Analysis by Blood Products During the analysis period 2005-2020, the global market for Cellular Blood components is projected to remain the largest among all other Blood Products with a market share of XX.XX % by 2020. In terms of market value, Cellular Blood components are estimated at US$ XX.XX billion for 2012 and are projected to reach US$ XX.XX billion by 2020. Plasma Derived products is expected to register the fastest growth during the analysis period with a CAGR of XX.XX %. Exhibit 6. Blood Components - Global Value Market Estimations & Predictions (2005 -2020) by Type for Plasma Products, Cellular Components and Whole Blood in US$ Billion Year/Type Plasma Products Cellular Components Whole Blood Total 2005 XX.XX XX.XX XX.XX XX.XX 2006 XX.XX XX.XX XX.XX XX.XX 2007 XX.XX XX.XX XX.XX XX.XX 2008 XX.XX XX.XX XX.XX XX.XX 2009 XX.XX XX.XX XX.XX XX.XX 2010 XX.XX XX.XX XX.XX XX.XX 2011 XX.XX XX.XX XX.XX XX.XX 2012 XX.XX XX.XX XX.XX XX.XX 2013 XX.XX XX.XX XX.XX XX.XX 2014 XX.XX XX.XX XX.XX XX.XX 2015 XX.XX XX.XX XX.XX XX.XX 2016 XX.XX XX.XX XX.XX XX.XX 2017 XX.XX XX.XX XX.XX XX.XX 2018 XX.XX XX.XX XX.XX XX.XX 2019 XX.XX XX.XX XX.XX XX.XX 2020 XX.XX XX.XX XX.XX XX.XX %CAGR XX.XX XX.XX XX.XX XX.XX © RIT Figures, 2013 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 US$ Billion Plasma Products CellularComponents Whole Blood
  • Exhibit 7. Blood Products - Global Value Market Estimations & Predictions (2005 -2020) by Type for Blood Components, Blood Testing & Collecting Devices and *Other in US$ Billion Year /Products Blood Components Blood Testing & Collecting Devices Other Total 2005 XX.XX XX.XX XX.XX XX.XX 2006 XX.XX XX.XX XX.XX XX.XX 2007 XX.XX XX.XX XX.XX XX.XX 2008 XX.XX XX.XX XX.XX XX.XX 2009 XX.XX XX.XX XX.XX XX.XX 2010 XX.XX XX.XX XX.XX XX.XX 2011 XX.XX XX.XX XX.XX XX.XX 2012 XX.XX XX.XX XX.XX XX.XX 2013 XX.XX XX.XX XX.XX XX.XX 2014 XX.XX XX.XX XX.XX XX.XX 2015 XX.XX XX.XX XX.XX XX.XX 2016 XX.XX XX.XX XX.XX XX.XX 2017 XX.XX XX.XX XX.XX XX.XX 2018 XX.XX XX.XX XX.XX XX.XX 2019 XX.XX XX.XX XX.XX XX.XX 2020 XX.XX XX.XX XX.XX XX.XX CAGR% XX.XX XX.XX XX.XX 11.54 *Other Includes Artificial Blood and Research © RIT Figures, 2013 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 US$ Billion Blood Components Blood Testing& Collecting Devices Other
  • Exhibit 8. Blood Products – Global Value Market Shares (2010, 2015 & 2020) by Type for Blood Components, Blood Testing & Collecting Devices, and *Other Year /Products Blood Components Blood Testing & Collecting Devices Other Total 2010 XX.XX XX.XX XX.XX 100 2015 XX.XX XX.XX XX.XX 100 2020 XX.XX XX.XX XX.XX 100 *Other Includes Artificial Blood and Research © RIT Figures, 2013
  • Analysis of Global Plasma Products by Type Global Blood Plasma Products market was estimated at US$XX billion in 2012 and is projected to touch US$ XX billion by 2020 at a CAGR of XX%. Global Immunoglobulin market is the largest product segment valued at US$XX billion in 2012 and is projected to reach US$XX billion by 2020. Blood Clotting factors market is expected to reach US$XX billion by 2020, registering a CAGR of XX% during the analysis period 2005-2020. Exhibit 9. Blood Plasma – Global Value Market Estimations & Predictions (2005 -2020) by Type for Immunoglobulins, Clotting Factors, Albumin and #Other in US$ Billion Year/ Type Immunoglobulins Clotting Factors Albumin Other Total 2005 XX.XX XX.XX XX.XX XX.XX XX.XX 2006 XX.XX XX.XX XX.XX XX.XX XX.XX 2007 XX.XX XX.XX XX.XX XX.XX XX.XX 2008 XX.XX XX.XX XX.XX XX.XX XX.XX 2009 XX.XX XX.XX XX.XX XX.XX XX.XX 2010 XX.XX XX.XX XX.XX XX.XX XX.XX 2011 XX.XX XX.XX XX.XX XX.XX XX.XX 2012 XX.XX XX.XX XX.XX XX.XX XX.XX 2013 XX.XX XX.XX XX.XX XX.XX XX.XX 2014 XX.XX XX.XX XX.XX XX.XX XX.XX 2015 XX.XX XX.XX XX.XX XX.XX XX.XX 2016 XX.XX XX.XX XX.XX XX.XX XX.XX 2017 XX.XX XX.XX XX.XX XX.XX XX.XX 2018 XX.XX XX.XX XX.XX XX.XX XX.XX 2019 XX.XX XX.XX XX.XX XX.XX XX.XX 2020 XX.XX XX.XX XX.XX XX.XX XX.XX CAGR% XX.XX XX.XX XX.XX XX.XX XX.XX #Other Includes Proteins & Minerals © RIT Figures, 2013 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 US$ Billion Immunoglobulins ClottingFactors Albumin Other
  • Exhibit 10. Blood Plasma – Global Value Market Shares (2010, 2015 & 2020) by Type for Immunoglobulins, Clotting Factors, Albumin and #Other Year/ Type Immunoglobulin Clotting Factors Albumin Other Total 2010 XX.XX XX.XX XX.XX XX.XX 100 2015 XX.XX XX.XX XX.XX XX.XX 100 2020 XX.XX XX.XX XX.XX XX.XX 100 #Other Includes Proteins & Minerals © RIT Figures, 2013
  • Analysis by Blood Testing & Collecting Devices Growing at a CAGR of XX%, Global Blood Testing and Collecting Devices market was estimated at US$XX billion in 2012 and is projected to touch US$XX billion by 2020. Global Blood Management & Monitoring Instruments market is projected to be the largest and fastest growing market during the analysis period 2005-2020. Exhibit 11. Blood Testing & Collecting Devices - Global Value Market Estimations & Predictions (2005 - 2020) by Type for Management and Monitoring Instruments, Immunoassays and ^Other in US$ Billion Year/Devices Management and Monitoring Instruments Immunoassays Other Total 2005 XX.XX XX.XX XX.XX XX.XX 2006 XX.XX XX.XX XX.XX XX.XX 2007 XX.XX XX.XX XX.XX XX.XX 2008 XX.XX XX.XX XX.XX XX.XX 2009 XX.XX XX.XX XX.XX XX.XX 2010 XX.XX XX.XX XX.XX XX.XX 2011 XX.XX XX.XX XX.XX XX.XX 2012 XX.XX XX.XX XX.XX XX.XX 2013 XX.XX XX.XX XX.XX XX.XX 2014 XX.XX XX.XX XX.XX XX.XX 2015 XX.XX XX.XX XX.XX XX.XX 2016 XX.XX XX.XX XX.XX XX.XX 2017 XX.XX XX.XX XX.XX XX.XX 2018 XX.XX XX.XX XX.XX XX.XX 2019 XX.XX XX.XX XX.XX XX.XX 2020 XX.XX XX.XX XX.XX XX.XX CAGR% XX.XX XX.XX XX.XX XX.XX ^Other Includes Nucleic Acid Test (NAT) and Blood Grouping © RIT Figures, 2013 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 US$ Billion Managementand Monitoring Instruments Immunoassays Other
  • Exhibit 12. Blood Testing & Collecting Devices - Global Value Market Shares (2010, 2015 & 2020) by Type for Management and Monitoring Instruments, Immunoassays and ^Other Year/Devices Management and Monitoring Instruments Immunoassays Other Total 2010 XX.XX XX.XX XX.XX 100 2015 XX.XX XX.XX XX.XX 100 2020 XX.XX XX.XX XX.XX 100 ^Other Includes Nucleic Acid Test (NAT) and Blood Grouping © RIT Figures, 2013
  • MIR029: Blood – Components, Testing & Collection – A Market Insight Report, January 2012 © RI Technologies - www.researchimpact.com Sample Page - 18 IV. PRODUCT/TECHNOLOGY RESEARCH Blood: The Life Stream in the Body Blood is the most important and essential body fluid which is termed as a tissue in medical terms. The various medical terms related to blood are derived from the Greek word hemo- and hemato. In medical science, blood is defined as a special type of connective tissue which originates from the bones and contains prospective molecular fibers in fibrinogen form Blood is responsible for conveying the various nutrients, oxygen, minerals and other essential substances into the various parts of the body. The blood donations carried out is aimed at saving the life of individuals who have either lost blood in accidents or surgeries. Blood is also required to treat people with severely low platelet count and anaemic condition. Effective screening and tests prior to administration of blood help to maintain safety and minimize transfusion diseases. These safety measures help both the donor and the recipient. In case of vertebrates, the main component of the blood is a liquid substance called blood plasma. The Plasma liquid contains around 60% of blood fluid. This fluid comprises of 90% water with dissolved minerals ions, proteins, glucose, hormones, platelets, blood cells and carbon dioxide which plays a vital role in conveying excretory products. The blood consists of two types of blood cells; they are red blood cells which are commonly called as erythrocytes or RBC’s in short and white blood cells, called thrombocytes or WBC’s. The most abundantly found cells in the vertebrate blood are the red blood cells. The red blood cell comprises of haemoglobin which is a type of protein rich in iron content. It is mainly responsible for conveying the oxygen by reversibly binding to the respiratory gas. It enhances the solubility in blood. Further, the carbon dioxide content is completely conveyed using extra cellular dissolving in plasma in the form of bicarbonate ion. The blood of vertebrates appears bright red in colour due to the presence of haemoglobin.  Some animals like molluscs and crustaceans make use of hemocyanin for conveying the oxygen in place of haemoglobin.  Similarly some of the insects and phylum molluscs make use of a typical fluid called haemolymph in place of the blood. The only difference between this fluid and the blood is that fluid is not enclosed in a circulatory system.  Another important observation is in majority of the cases, this fluid does not contain the oxygen- conveying substances like the haemoglobin. This is primarily because their body composition is very small and their tracheal system is more than sufficient to convey oxygen to the various parts of the body.  The vertebrates containing jaws are exclusively designed. They possess an adaptive immune system containing white blood cells on a majority.
  • MIR029: Blood – Components, Testing & Collection – A Market Insight Report, January 2012 © RI Technologies - www.researchimpact.com Sample Page - 19  The white blood cells play prominent role in restricting the entry of parasites and defying infections.  The blood clotting takes place due to the vital activities of Platelets.  The phylum arthropods contain haemocytes as a prominent part of their immune system. They make use of haemolymph in their immune system. The circulation of blood inside the blood vessels takes place by the continuous pumping action of the heart. In animals which contain lungs, the blood conveyed through the arteries also carries oxygen from inhaled air to the various tissues of the body. Further, the exhaled air which contains carbon dioxide and waste products of metabolism produced by cells is transported by the venous blood. BLOOD – COMPONENTS, TESTING & COLLECTION – THE OUTLOOK A sudden increase in new infections all over the world is a matter worry to the blood banking and blood products industry. Even though the people were very alert regarding the different infections and health workers tried to reduce the severity of the infection, the industry is yet to overcome difficulties like security, and the accessibility to good quality blood. This knowledge has lead to very strict safety measurements being taken for both the donors as well as the blood screening (blood) banks which has to be adhered to before any transfusion is carried out. The risk of diseases spread via transfusions has decreased by conduction of thorough testing and screening techniques and also with the assistance from the latest technologies. The condition did improve on the whole but there are still cases of diseases being transmitted through blood transfusions in developing as well as under-developed countries. Although there were movements that were carried out in these countries, it was only criticized and very few donors volunteered. As more and more consumers are insisting in a zero-risk blood supply, large investments are being put into the development of pathogen reduction solutions which is carried out by small biotechnology firms and also large medical device manufacturers. Providing information which is associated with the efficiency and safety levels of pathogen inactivation systems that arises from research labs as well as clinical setting will give them an impetus for enhanced market penetration. The growth of new technologies which has the ability to destroy a wide range of pathogens and at the same time not cause damage to the blood products will probably improve the market expansion. As new technologies are being developed, the pathogen reduction Blood market is not likely to face tough competition. The technologies that were there earlier like solvent/detergent plasma were considered unsafe and could not be generally applied whereas the new technologies will not considerably reduce the window of time from the initial infection and the point at which the pathogen is identified. The blood banks now readily await a safe technology that will combine with their processing systems and decrease the danger of transfusion-related infections to almost nil. The success of the market is ascertained by the capacity to provide cost-effective technologies with a wide kill range, strong safety profile and the effortlessness in the application. The provision to persuade the buyer decision making processes combined with first-mover advantage will be significant in achieving a competitive edge……
  • MIR029: Blood – Components, Testing & Collection – A Market Insight Report, January 2012 © RI Technologies - www.researchimpact.com Sample Page - 20 About RI Technologies RI Technologies is a premier source of market research on the Biotechnology & Healthcare sector. We emphasize on factual insights and forecasts with maximum global coverage. RI Technologies is constantly monitoring the biotechnology & Healthcare industry, tracking market trends, and forecasting industry based on specialized analysis. The life sciences sector is an ever growing marketplace with emerging technologies in areas of discovery, design and development. Research – As Good as the Methodology is!  Gauging Competitive Intelligence  Identifying Key Growth Areas and Opportunities  Understanding Geographic Relevance to Product  Knowing Regional Market Sizes and Growth Opportunities and Restraints  Keeping Tab on Emerging Technologies  Equity Analysis  Tapping New Markets © COPYRIGHT The copyright and publication rights to all RI Technologies' reports and other products are the property of the company. Plagiarism of any kind accounts to violation of copyright laws. Any type of reproduction of the material without express permission is not allowed. The buyer, under no circumstances, shall license, resell or repackage, or sell data without prior permission of the company. DISCLAIMER RI Technologies sells content in good faith. The company is not liable to the buyer for any implications arising out of the usage of data for any particular purpose. The company makes no representations or warranties for the accuracy or completeness of the data. While extreme caution and effort is practiced for data compilation and presentation, the company does not accept any responsibility for findings in the study which are a cumulative effort of primary and secondary research resources. The studies do not endorse or promote any product or company. RI Technologies, its affiliates, partners, distributors, and contractors are not liable for inaccuracies or incompleteness of the reports. User discretion is recommended for the usage of the data.